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PURPOSE. Intravitreal murine lineage-negative bone marrow (BM) hematopoietic cells slow
down retinal degeneration. Because human BM CD34þ hematopoietic cells are not precisely
comparable to murine cells, this study examined the effect of intravitreal human BM CD34þ
cells on the degenerating retina using a murine model.
METHODS. C3H/HeJrd1/rd1 mice, immunosuppressed systemically with tacrolimus and
rapamycin, were injected intravitreally with PBS (n ¼ 16) or CD34þ cells (n ¼ 16) isolated
from human BM using a magnetic cell sorter and labeled with enhanced green fluorescent
protein (EGFP). After 1 and 4 weeks, the injected eyes were imaged with scanning laser
ophthalmoscopy (SLO)/optical coherence tomography (OCT) and tested with electroreti-
nography (ERG). Eyes were harvested after euthanasia for immunohistochemical and
microarray analysis of the retina.
RESULTS. In vivo SLO fundus imaging visualized EGFP-labeled cells within the eyes following
intravitreal injection. Simultaneous OCT analysis localized the EGFP-labeled cells on the
retinal surface resulting in a saw-toothed appearance. Immunohistochemical analysis of the
retina identified EGFP-labeled cells on the retinal surface and adjacent to ganglion cells.
Electroretinography testing showed a flat signal both at 1 and 4 weeks following injection in
all eyes. Microarray analysis of the retina following cell injection showed altered expression of
more than 300 mouse genes, predominantly those regulating photoreceptor function and
maintenance and apoptosis.
CONCLUSIONS. Intravitreal human BM CD34þ cells rapidly home to the degenerating retinal
surface. Although a functional benefit of this cell therapy was not seen on ERG in this rapidly
progressive retinal degeneration model, molecular changes in the retina associated with
CD34þ cell therapy suggest potential trophic regenerative effects that warrant further
exploration.
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Retinal degenerative conditions, such as AMD and hereditaryretinal degeneration, remain common causes of irreversible
vision loss.1,2 Tissue regeneration is possible with stem cell
therapy, and stem cells are being explored as a potential
treatment for retinal degenerative disorders.3,4 Recent advances
in stem cell research have made clinical studies possible in
human patients with retinal degenerative disorders. Early phase
clinical trials have been initiated using subretinal transplanta-
tion of fetal neural stem cells or retinal pigment epithelial cells
derived from embryonic or induced pluripotent stem cells as
treatment for hereditary or nonexudative AMD (www.
clinicaltrials.gov; available in the public domain).5–7 These cell
therapies appear to be well tolerated and may be capable of
improving visual function. However, the use of these stem cells
raises ethical and regulatory issues. In addition, allogeneic
subretinal cell transplantation requires surgical manipulation of
the central retina and prolonged systemic immunosuppression.
An alternative cell therapy approach that is being explored
in clinical trial is intravitreal administration of autologous adult
stem cells.8,9 This approach would be easier and potentially
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safer to administer because no systemic immunosuppression
or retinal surgery would be needed. It has been shown in a
murine model that intravitreal injection of autologous bone
marrow (BM)-derived lineage negative hematopoietic stem
cells can slow down hereditary retinal degeneration.10,11 One
small phase 1 clinical study in Brazil treated patients with
hereditary retinal degeneration with a single intravitreal
administration of autologous mononuclear cells from the BM
aspirate.12 The treatment was well tolerated, but visual benefit
was minimal.
In human BM, hematopoietic stem cells are often charac-
terized by the CD34þ cell surface marker. The mononuclear
cell fraction of human bone marrow is a crude cellular mixture
that contains a very low concentration of CD34þ cells
(approximately 2%).13 Thus, by purifying the CD34þ cells
from the BM aspirate and concentrating them, a potentially
safer and more effective cell therapy might be delivered to the
eye. Preclinical studies in eyes with acute ischemia-reperfusion
injury or diabetic retinopathy demonstrated that these cells
rapidly homed into the damaged retinal vasculature, where
they appeared to play a role in tissue repair.14 No long-term
ocular or systemic safety issues were noted with intravitreal
administration of human BM CD34þ cells in NOD-SCID mice
with acute ischemia-reperfusion injury.15 These human cells
could be identified incorporated into the mouse retinal
vasculature even 6 months following administration.
To date, there are no animal data investigating the effect of
intravitreally administered human CD34þ cells from BM in eyes
with retinal degeneration. However, a phase 1 clinical trial has
been initiated exploring the effect of autologous intravitreal
BM CD34þ cell therapy in patients with vision loss from retinal
degeneration.8 No adverse effects were noted to be associated
with the cell therapy during the 6-month study follow-up.
Some eyes had improvement in visual function. Adaptive
optics optical coherence tomography imaging showed new
punctate hyperreflective changes within the degenerating
retina suggestive of intraretinal incorporation of the cells
injected into the vitreous cavity.8 However, no histologic
correlate is available to correctly interpret these in vivo retinal
imaging changes in human eyes.
The purpose of this current study is to further characterize
the effect of the human CD34þ cells from BM on the
degenerating retina following intravitreal administration using
a murine model of hereditary retinal degeneration. By using an
in vivo retinal imaging device designed for simultaneous
multimodal imaging of murine eyes by scanning laser
ophthalmoscopy (SLO) and optical coherence tomography
(OCT), cellular changes within the retina potentially can be
visualized in vivo following intravitreal injection of fluores-
cently labeled cells.16 By conducting molecular, functional, and
histologic analysis of the degenerating retina following cell
therapy, the potential therapeutic effect of these cells on the
degenerating retina can be further investigated. The findings of
this study would be important before exploring the potential
therapeutic effect of intravitreal BM CD34þ cells in a larger
clinical trial for patients with degenerative retinal conditions.
METHODS
Animals
This study protocol was approved by the Institutional Animal
Care and Use Committee at the University of California Davis
before initiation. The study was conducted according to the
approved protocol and in accordance with the ARVO
statement for the Use of Animals in Ophthalmic and Vision
Research.
Thirty-two C3H/HeJ mice homozygous for the rd1 mutation
(C3H/HeJrd1/rd1; Jackson Laboratories, Sacramento, CA, USA;
strain 000659) were used in this study. All mice were male and
3 weeks of age at the initiation of the study and maintained at
the Vivarium of the Institution for Regenerative Cures at the
University of California Davis, which is a pathogen-free barrier
facility that allows housing of immunosuppressed animals.
Within 2–3 days following arrival to the vivarium, systemic
immunosuppression was initiated in the mice by placement of
the Alzet micro-osmotic pump (see section on Immunosup-
pression for details). Five days after initiating systemic
immunosuppression, intravitreal injection of human CD34þ
cells or saline (PBS) was performed only in the right eye under
isoflurane anesthesia (see section on Intravitreal Injection for
detail). At 1 and 4 weeks following intravitreal injections, the
mice underwent simultaneous in vivo retinal imaging using a
combined scanning laser ophthalmoscopy (SLO) and optical
coherence tomography (OCT) imaging16 or electroretinogra-
phy (ERG) testing. Following testing, the animals were
euthanized, and the right eyes were harvested promptly for
immunohistochemical studies or total RNA isolation. The
detailed descriptions of each of the steps of the procedure
are outlined below.
Immunosuppression
All mice were started on systemic immunosuppression 5 days
before intravitreal injection to prevent cross-species rejection
of human cells.17 Immunosuppression was achieved by
implantation of an Alzet micro-osmotic pump (model 1004;
Durect Corporation, Cupertino, CA, USA), which releases
immunosuppressive agents (Tacrolimus and Rapamycin) at a
constant rate (1 lg/g/day each) over 1 month. Implantation
was performed in all mice at 3 weeks of age.
The Alzet pumps were preloaded with FK506/rapamycin,
which were diluted in 50% dimethyl sulfoxide (DMSO)/50%
polyethylene glycol (PEG) and incubated in Normosol-R at
378C for 48 hours prior to implantation. FK506 and rapamycin
were purchased from InVivoGen (San Diego, CA, USA).
Prior to subcutaneous implantation of Alzet pump to the
back of the mice, mice were anesthetized using isoflurane (2–
3% in oxygen). Hair was removed from the back using Nair
Hair Removal Lotion (Church & Dwight Co., Inc., Ewing, NJ,
USA). After hair removal, the underlying skin was cleaned with
betadine. After 2 minutes, the skin was wiped with an alcohol
pad. A small full-thickness skin incision between the scapulae
was created, which was tunneled subcutaneously toward the
tail and along the back to provide a subcutaneous space large
enough for the pump placement. The pump was positioned
subcutaneously with the flow moderator portion of the pump
pointing toward the tail and away from the incision. The skin
incision was then closed with 6-0 silk sutures.
CD34þ Cell Isolation and EGFP Labeling
Fresh human BM aspirate was purchased from AllCells
(Alameda, CA, USA) and obtained for the scheduled day of
use. The BM aspirate for this study was obtained from a 38-
year-old healthy male donor, and CD34þ cells were isolated
from the BM aspirate according to the protocol used for the
clinical trial.8 The fresh BM aspirate was diluted 1:1 with PBS
and immediately underwent Ficoll centrifugation. After centri-
fugation, the buffy coat was aspirated to collect the mononu-
clear cells. The buffy coat was diluted and washed with PBS
and centrifuged to pellet all mononuclear cells. The cell pellet
was then resuspended in PBS and counted using a hemacy-
tometer. To isolate the CD34þ cells, the Miltenyi human CD34
MicroBead Kit (Cat#130-046-702; Miltenyi Biotec, Inc., San
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Diego, CA, USA) was used to magnetically sort out the CD34þ
cells from the mononuclear cell fraction. This was done
following the manufacturer’s instructions.
To label the isolated CD34þ cells with enhanced green
fluorescent protein (EGFP), the isolated CD34þcells were then
cultured overnight at 378C/5% CO2 in a 35-mm dish in
hematopoietic stem cell (HSC) Proliferation Medium as
follows: Iscove’s Modified Dulbecco’s Medium (IMDM), peni-
cillin/streptomycin (13), L-glutamine (13), 10% fetal bovine
serum, stem cell factor (SCF; 50 ng/mL), thrombopoietin (TPO;
50 ng/mL), and FMS-like tyrosine kinase receptor-3 (FLT3)
ligand (50 ng/mL).18 The following day, the cells were counted
and transduced at multiplicity of infection (MOI) 20 with a
lentiviral vector containing EGFP and luciferase. Briefly, the
cells were pelleted and then resuspended in 50 lL HSC
proliferation medium, 10 lg/mL protamine sulfate, and virus at
MOI 20 in a cryo-vial. The vial was incubated for 5 hours at
378C/5% CO2 and was mixed every hour to ensure maximum
exposure of the cells to the virus. The cells were then
resuspended in 5 mL HSC proliferation medium and replated
into a 35-mm dish overnight. The following day, the cells were
pelleted, washed in PBS, and then resuspended at 50,000 cells/
lL in PBS for intravitreal injection.
Intravitreal Injections
Intravitreal injections were performed 5 days after Alzet Pump
implantation to allow for immunosuppression to be achieved
(i.e., 4 weeks of age). An intravitreal injection was performed
once in the right eye of each mouse. It was performed pars
planar and transconjunctivally under isoflurane (2–3% in
oxygen) anesthesia. After instilling a drop of 5% betadine
solution into the fornix, a sterile 33-G needle attached to a
Hamilton syringe was used to deliver 1 lL solution per eye. The
animals were injected with either EGFP-labeled CD34þ cells
from human BM (n¼ 16 mice, 50,000 CD34þ cells in 1 lL) or
saline (n ¼ 16 mice, 1 lL PBS). Following injection, antibiotic
eye ointment was applied to the injected eye.
Electroretinography
In preparation for ERG testing, the mice were dark adapted for
12 or more hours prior to testing. Pupils were fully dilated
prior to testing using topical tropicamide 0.5% and phenyl-
ephrine 2.5%. For anesthesia, the animals were injected
intraperitoneally with ketamine (15 lg/g) and xylazine (7 lg/
g). Proparacaine 1% topical analgesic was administered to the
eyes just prior to ERG electrode placement. Mice were placed
on a rodent body warming plate for the duration of the
procedure, and ERG was performed bilaterally. Reference
needle electrodes were reconfigured into a small circular shape
and bent 908 to position just over the cornea with use of
goniosoft contact gel, and a reference electrode was placed
subdermally between the ears towards the nose. Electrodes
were held in place with use of small alligator clips.
Electroretinographs were generated under a variety of condi-
tions, including scotopic single flash at intensities of64,14,
8,4, 0, and 6 dB; photopic white single flash at intensities of
64,14,8,4, 0, and 6 dB; and photopic white 30-Hz flicker
at 0 dB. Recordings were made using LKC Big Shot, UTAS
Visual Electrodiagnostic System with EM for Windows Version
1.3 (LKC Technologies, Inc., Gaithershung, MD, USA).
Retinal Imaging
Animals were imaged 1 or 4 weeks after intravitreal injection. A
multimodal retinal imaging system specifically designed and
built for in vivo mouse retinal imaging was used. This system
integrates multichannel SLO and OCT and allows simultaneous
collection of complementary information from the tissue,
greatly simplifying data registration and analysis.16 With its
customized scanning head, the scanning field view (FOV) can
be up to 508, whereas software control allows limiting the
scanning to any square subfield of the larger field. With a
customized contact lens mounted to the scan head, the mouse
cornea was kept hydrated and clear, greatly facilitating mouse
handling during a single imaging session.
The combined SLO and OCT imaging platform is compactly
arranged in an 83 8-in frame and sits on a platform that can be
easily tilted and translated, providing precision alignment with
respect to the eye of the anesthetized mouse.
The mouse retinal imaging was performed under isoflurane
(2–3% in oxygen) inhalation anesthesia. A heating pad was
used to maintain normal body temperature and avoid the
development of ‘‘cold cataracts’’ during imaging.19 The head
was held rigidly by a ‘‘bite-bar’’ that also served to keep its
snout inside the gaseous isoflurane anesthetic delivery tube.
SLO Subsystem. A super-continuum laser (SC-400; Fianium,
Inc., Eugene, OR, USA) is used as the light source for the SLO
subsystem. By changing emission filters, different excitation
wavelengths can be chosen. In the experiments presented here
we restricted the light source spectrum to spectral band that
provides strong excitation for EGFP, single bandpass filter
(MF469-35; Thorlabs, Inc., Newton, NJ, USA), and chose a
corresponding dichroic mirror (DM1; Di01-R488/561; Semrock,
Inc., Rochester, NY, USA) and filter (FF01-525/45; Semrock)
(filter 2) for EGFP emitted fluorescence light to be detected
using a photomultiplier tube (PMT) (H7422-40; Hamamatsu
Photonics, K.K., Shizuoka, Japan). A reflected light signal was
acquired by separate PMT (H7422-20; Hamamatsu).
OCT Subsystem. The Fourier domain (i.e., spectral
domain) SD-OCT system imaging beam was optically integrated
with the SLO subsystem via the second dichroic mirror (DM2).
We used a broadband light source with a 132-nm bandwidth
centered at 860 nm (Broadlighter 890; Superlum Diodes Ltd.,
Cork, Ireland), which provides ~2-lm theoretical axial
resolution in tissue. A custom spectrometer with a high-speed
line CMOS camera (Sprint spL4096-140km; Basler Electronics,
Highland, IL, USA) was used as the OCT detector. The OCT
system operates at speeds up to 125,000 A-scan/s.20
Contact Lens. A 0-diopter (D) mouse contact lens (Unicon
Corporation, Osaka, Japan) was used to keep the mouse cornea
hydrated. The contact lens was physically mounted on the
scanning head, rather than being placed on the mouse cornea.
With this approach, it is easier to keep the outer surface of the
contact lens clean and, given that the mouse’s head is affixed to
a bite-bar embedded in the isoflurane delivery system, to
maintain stable and highly reproducible imaging for periods of
an hour or more if needed.
Tissue Processing
At 1 and 4 weeks after intravitreal injections, half of the mice
from each study group (i.e., n ¼ 8 per study group per time
point) were euthanized by asphyxiation with gaseous CO2 in a
closed chamber following retinal imaging or ERG testing.
Following euthanasia, the right eye was harvested for
immunohistochemistry or microarray analysis.
For immunohistochemistry, the right eyes of four mice in
each group and time point were enucleated, fixed in 10%
neutral buffered formalin, and embedded in paraffin.21 For
orientation in paraffin, the superior region of each eye was
marked using tissue dye (catalog #1003-6, The Davidson
Marking System; Bradley Products, Inc., Bloomington, MN,
USA) before enucleating with curved scissors. The eyes were
fixed by immersing in freshly prepared 10% neutral buffered
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formalin overnight after enucleating and subsequently embed-
ded in paraffin maintaining orientation using the tissue dye
marker. Sections were cut using a Leica RM2125RT microtome
(Leica, Nussloch, Germany) at 6 lm, placed on SuperFrost Plus
microscope slides, and dried overnight at room temperature.
Based on the previous orientation of each eye in the paraffin
embedding step, a section through the optic disk represented a
sagittal section.
For microarray analysis, the right eyes of four mice in each
group at each time point were removed using curved forceps
and glued to a Petri dish with superglue for stabilization. A
circumferential cut was made dorsal to the limbus, removing
the anterior segment of the eye. Retinal tissue was removed
after severing the optic nerve and collected within 1 minute
after death of the animal. The collected retina was immediately
placed in 300 lL RNALater, placed on ice, and stored at208C.
Immunohistochemistry
Immunohistochemistry was performed by removing paraffin in
xylene followed by hydration through graded alcohols and into
PBS before blocking at room temperature in PBS containing
0.3% Triton X-100 and 5% normal donkey serum. Slides were
then incubated overnight at 48C with 2 lg/mL rabbit anti-GFP
(Life Technologies, Carlsbad, CA, USA). After primary antibody
exposure, sections were washed in PBS containing 0.3% Triton
X-100 and then incubated at 378C with 1 lg/mL Cy3 conjugated
donkey anti-rabbit IgG (Jackson ImmunoResearch Labs, West
Grove, PA, USA) diluted in PBS for 30 minutes, washed in PBS,
and cover-slipped using 40,6-diamidino-2-phenylindole (DAPI)
Fluoromount G (Southern Biotech, Birmingham, AL, USA).
Secondary antibody background staining was tested using an
isotype-matched immunoglobulin (rabbit IgG; Jackson Immu-
noResearch) at the same concentration as the primary antibody.
Sections were also stained with anti-human nuclei monoclonal
antibody (EMD Millipore, Billerica, MA, USA) to identify all
injected human cells that may not have been labeled with GFP.
The secondary antibody used was Alexa Fluor 647–conjugated
donkey anti-mouse IgG (Millipore).
Slides were viewed and digitized images captured using a
Nikon Eclipse E800 with epifluorescence and QCapture
software (QImaging, Surrey, British Columbia, Canada). Digi-
tized phase contrast with fluorescence images were captured
using a Nikon Eclipse E800 microscope and QCapture software
(QImaging).
Microarray Analysis
RNA Isolation. Qiagen’s miRNeasy isolation kit (Valancia,
CA, USA) was used to isolate total RNA. As a first step, tissue
was placed in Qiazol and passed through a 1-mL syringe
attached to a 17-G needle several times. RNA samples were run
on an Agilent BioAnalyzer microfluidics chip RNA Nano 6000
(Agilent Technologies, Santa Clara, CA, USA) to assess quality
and quantity. Of four samples, the three samples having the
highest quality (RNA Integrity Number [RIN] ‡ 7 value) were
labeled as probes for the Affymetrix GeneChip microarrays
(Affymetrix, Santa Clara, CA, USA).
Microarray Probe Labeling. Samples of RNA were labeled
using 0.050 lg total RNA, following the manufacturer’s
protocol for GeneChip WT Terminal Labeling and Controls
Kit (Affymetrix) combined with Ambion WT Expression Kit
(Ambion, Inc., Foster City, CA, USA). After labeling, the probes
were hybridized to the Affymetrix Mouse Transcriptome Assay
1.0 (MTA1) GeneChip microarrays. This array analyzes
expression of >114,000 transcripts for protein coding genes
and >101,000 transcripts for nonprotein coding content
(noncoding RNA, such as microRNA, pseudogenes, and rRNA).
Hybridization was performed at the University of California
Davis Genome Center Microarray Core Facility using a standard
manufacturer’s procedure (Affymetrix). The total dataset
included 12 GeneChip microarrays.
Microarray Data Analysis. Microarray data were analyzed
using Affymetrix Expression Console followed by Transcrip-
tome Analysis Console 3.0 and WikiPathways for biologically
relevant changes of expression in genes and related pathways
of the retina. A heatmap was generated using hierarchical
clustering analysis by Partek Genomics Suite software (Partek,
Inc., St. Louis, MO, USA).
Statistical Analysis of Microarrays. One-way ANOVA
was used in the Transcriptome Analysis Console to identify
statistically significant genes at a significance level of P  0.05.
We used the standard approach of using a P value (P  0.05) as
the primary criterion followed by fold change (FC) of at least
1.5 (1.5 ‡ FC ‡ 1.5) as the secondary criterion to select
differentially expressed genes. This approach ensures control
of false-positive error and preserves the desired biological
significance.22
RESULTS
The Table summarizes the number of mice in each study
group, length of follow-up, and tests performed in this study.
All mice had hereditary retinal degeneration (rd1) and were
immunosuppressed systemically for the study duration. Only
the right eye was injected and studied. Sixteen mice were
injected with human CD34þ cells from bone marrow and 16
were injected with PBS. Half of the mice in each group were
killed and analyzed 1 week following intravitreal injection,
TABLE. Summary of Animals, Treatments, Follow-Up, and Studies Performed in This Study
Group Mice OD OS Follow-up Studies
CD 34þ Cell-Treated 8 CD34þ Control 1 week Four mice underwent ERG and eyes harvested for
immunohistochemistry; four mice underwent SLO-OCT
imaging and retinas harvested for microarray
8 CD34þ Control 4 weeks Four mice underwent ERG and eyes harvested for
immunohistochemistry; four mice underwent SLO-OCT
imaging and retinas harvested for microarray
Control mice 8 PBS Control 1 week Four mice underwent ERG and eyes harvested for
immunohistochemistry; four mice underwent SLO-OCT
imaging and retinas harvested for microarray
8 PBS Control 4 weeks Four mice underwent ERG and eyes harvested for
immunohistochemistry; four mice underwent SLO-OCT
imaging and retinas harvested for microarray
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and the other half were killed 4 weeks after intravitreal
injection.
In Vivo Retinal Imaging
Combined SLO and OCT imaging of the retina of the right
eye was performed on animals at 1 or 4 weeks following
intravitreal injection of CD34þ cells or PBS. The CD34þ
cells injected into mice eyes were labeled with EGFP to
enable detection of the cells in the eye in vivo using SLO
imaging. Scanning laser ophthalmoscopy fundus imaging
detected the EGFP-labeled cells in eyes of mice that
received these cells intravitreally. In contrast, eyes that
received intravitreal PBS injection had only background
fluorescence (Figs. 1A, 1B).
Simultaneous OCT and SLO imaging of the retina was
conducted to obtain corresponding OCT B-scan cross-sectional
images of the retina to determine the axial location of the
EGFP-labeled cells seen on SLO fundus image. As shown in
Figure 1C (white solid arrow), multiple focal retinal surface
irregularities are noted in eyes injected with CD34þ cells
resulting in a ‘‘saw-tooth’’ appearance at the retinal inner
surface. These surface irregularities correspond in size and
location to EGFP-labeled cells seen on SLO fundus photography
and likely represent the presence of the EGFP-labeled CD34þ
cells on the surface of the retina. In addition, Figure 1C (open
arrow) also shows some mildly hyperreflective deposits seen
within the inner retinal layers suggestive of intraretinal
incorporation of the cells into these layers. In contrast, the
OCT B-scan images of the retina of an eye injected with PBS
showed a relatively smooth retinal surface (Fig. 1D). No focal
hyperreflective abnormalities within the inner retinal layers are
seen in the PBS-injected eyes.
At 4 weeks following intravitreal injection, a diffuse loss of
the outer retina was noted on B-scan OCT images of the retina
in eyes treated with either intravitreal CD34þ cells or
intravitreal PBS. There was no difference in the fluorescence
pattern on SLO image of eyes treated with CD34þ cells at 4
weeks compared with 1 week after cell injection. Similarly, the
B-scan OCT images obtained of eyes at 4 weeks following cell
injection showed similar retinal surface irregularities as was
observed 1 week following CD34þ cell injection. No EGFP-
labeled cells were seen on SLO fundus imaging in PBS injected
eyes at 4 weeks following injection. No surface irregularities or
focal intraretinal hyperreflective changes were noted on B-scan
OCT images in PBS injected eyes after 4 weeks.
Immunohistochemical Analysis
Figure 2 illustrates the immunohistochemical analysis of eyes 1
week following intravitreal injection of EGFP-labeled CD34þ
cells. EGFP-labeled cells are detected on the retinal surface and
adjacent to the ganglion cells. For more detailed analysis,
digitalized phase contrast microscopy imaging was used to
study the histologic sections that demonstrated cells on top of
the retina, adjacent to the internal limiting membrane (ILM),
and ganglion cells (Figs. 1E, 1F). No EGFP-labeled cells were
seen in the retina in eyes treated with PBS. Minimal
background staining was seen. Similar observations were
noted 4 weeks following intravitreal injection of EGF-labeled
cells (data not shown; i.e., EGFP-labeled cells were detected on
the retinal surface in eyes treated with CD34þ cells, similar to
findings 1 week following cell injection). Additional immuno-
histochemical analysis of eyes treated with CD34þ cells using
an anti-human nuclei antibody detected human cells on the
retinal surface and adjacent to the ganglion cells, similar to
findings using anti-GFP.
Electroretinography
The ERG testing revealed virtually flat signal recordings in all
eyes under a variety of scotopic and photopic testing
conditions. There were no differences in ERG testing between
CD34þ-injected eyes and PBS-injected eyes at either 1 or 4
weeks following intravitreal injection. There also was no
FIGURE 1. In vivo retinal imaging using combined SLO and Fourier-
domain OCT retinal imaging in rd1 mice following intravitreal injection
of EGFP-labeled CD34þ cells or PBS. (A) At 1 week following
intravitreal injection of EGFP-labeled CD34þ cells, SLO fundus image
of the right eye shows presence of EGFP-labeled cells in the eye. (B) At
1 week following intravitreal PBS injection, only background fluores-
cence is seen on SLO fundus image. (C) A B-scan OCT retinal image
taken 1 week following intravitreal injection of EGFP-labeled CD34þ
cells shows dramatic retinal surface irregularities (white solid arrow)
with some focal mildly hyperreflective changes within the inner retinal
layers (open arrow). These focal changes within the retina and on the
surface of the retina colocalize to the fluorescent cells seen on SLO
image (A). (D) A B-scan OCT retinal image taken 1 week following
intravitreal injection of PBS shows a relatively smooth retinal surface
without the focal hyperreflective changes within the retinal layers seen
in cell-treated eyes (C). Although the outer retinal layer appears slightly
more defined in this image compared with C, this was not a consistent
finding. (E) Immunohistochemical analysis of the retina from rd1 mice
following intravitreal injection of EGFP-labeled CD34þ cells, showing
fluorescent cells on the retinal surface and adjacent to ganglion cells.
(F) Phase contrast microscopy imaging of the same section shown in E,
demonstrating the injected CD34þ cells on top of the retina, over the
internal limiting membrane.
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difference in the ERG signal between the injected right eye and
the contralateral untreated left eye (Fig. 3).
Microarray Analysis of the RNA in the Retina
Retinas from both CD34þ cell-treated and PBS-treated control
eyes were obtained at 1 and 4 weeks following intravitreal
injection, and the retinal RNA was analyzed for significant
changes in gene expression (i.e., FC over 1.5 and P < 0.05).
At 1 week following intravitreal injections, the expression
of 332 mouse genes was found to be significantly changed in
the retina collected from eyes treated with CD34þ cells
compared with the retina from eyes treated with PBS injection.
Analysis through Ingenuity Pathways Analysis (IPA) software
identified that the top canonical pathway that was significantly
affected was the phototransduction pathway (P < 0.001). IPA
also performs Top Upstream Regulator analysis, which
identifies a common transcription factor and a group of target
genes whose expression changed. The top affected upstream
regulator was CRX (P < 0.001), which has a known role in the
development and maintenance of photoreceptors.23,24 Another
significantly affected upstream regulator was NR2E3 (P <
0.001), which is important for photoreceptor development and
has been implicated in inherited retinal dystrophies.25 In
addition, 386 clusters of noncoding RNAs (microRNAs, small
nucleolar RNAs, long noncoding RNAs) demonstrated signifi-
cant changes in expression in eyes injected with CD34þ cells
compared with PBS-injected eyes. The full gene lists with
associated fold change of expression used for IPA analysis at 1
and 4 weeks are provided in Supplementary Tables S1 and S2.
At 4 weeks following intravitreal injections, the expression
of 86 mouse genes was found to be significantly changed in the
retina of eyes treated with CD34þ cells compared with the
retina from PBS-injected eyes. The top canonical pathway
significantly affected at this later time point was the G-protein
coupled receptor signaling pathway (P < 0.001). The top
affected upstream regulators included PAX3, which is involved
in neurogenesis,26 and Creb, which has been shown to have a
regulatory function in apoptosis.27 In addition, clusters of
noncoding RNAs (microRNAs, small nucleolar RNAs, long
noncoding RNAs) demonstrated significant changes in expres-
sion at this time point in CD34þ cell-injected eyes compared
with PBS-injected eyes. Hierarchical clustering analysis (heat-
map) of microRNAs dysregulated (ANOVA, P < 0.05) in the
retina following intravitreal injection of CD34þ stem cells and
controls shows that the most dramatic differences were at
week 1 and dampening at week 4 (Fig. 4).
A specific analysis of genes involved in the apoptosis
pathway was also performed. At 1 week, a majority of these
genes were down-regulated in the retina in eyes treated with
CD34þ cells compared with the retina in eyes injected with
PBS (Fig. 5A). At 4 weeks, this difference was diminished (Fig.
5B).
DISCUSSION
In this study, we used a murine model of hereditary retinal
degeneration (rd1) to study the effect of human BM CD34þ
stem cells on the degenerating retina following intravitreal
administration. We used an in vivo retinal imaging system
specifically designed for murine eyes, as well as immunohis-
tochemical techniques to localize these cells in the eye
following intravitreal administration. We then performed ERG
testing and microarray analysis to determine if the intravitreal
CD34þ cell treatment resulted in detectable functional or
FIGURE 2. Immunohistochemical analysis of the retina from rd1 mice following intravitreal injection of EGFP-labeled CD34þ cells versus PBS.
Analysis of the retina of eyes treated with intravitreal injection of EGFP-labeled CD34þ cells, the EGFP-labeled cells are detected within the vitreous
and adjacent to the ganglion cell layer (GCL) at 1 week following injection (A). No EGFP-labeled cells were detected in PBS injected eyes (B). The
tissue slides were blocked with 5% normal goat serum. Primary antibody used was anti-rabbit GFP. Secondary antibody used was Cy3 conjugated
donkey anti-rabbit IgG.
FIGURE 3. Electroretinogram of both eyes of rd1 mice at 1 week
following intravitreal injection of CD34þ cells in the right eye (i.e., 4
weeks of age) under scotopic and photopic conditions. The recording
is almost flat in both eyes under scotopic and photopic conditions. No
difference was noted between the CD34þ-treated eye (right) and
untreated left eye. No difference was noted between the CD34þ-
treated right eye and PBS treated right eye at 1 and 4 weeks following
injection. (OD, red line; OS, blue line).
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molecular changes in the retina suggestive of a therapeutic
effect.
The current study was conducted to better characterize the
effect of intravitreal injection of human BM CD34þ cells on the
degenerating retina. This information is timely and clinically
relevant because early clinical trials have been initiated
exploring intravitreal administration of BM mononuclear cells
or CD34þ cells as a potential therapy for various retinal
degenerative conditions. Based on published results, this cell
therapy appears to be feasible and without any major safety
issues.8–11 Potential visual benefit was observed in some study
eyes. Based on these encouraging clinical results, a larger
FIGURE 4. Hierarchical clustering analysis of microRNAs dysregulated (ANOVA, P < 0.05) in the retina of the mouse eyes following intravitreal
injection of CD34þ stem cells and controls at 1 and 4 weeks after injection. Red and blue colors in the heatmap represent induced and repressed
miRNAs, respectively. Scale bar denotes the linear values of fold change.
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clinical trial may be warranted to further explore the potential
efficacy of this cell therapy on retinal degenerative conditions.
However, before embarking on such a study, it would be
important to better characterize the effects of these cells on
the degenerating retina.
In our current study, the rd1 murine model was used
because it is the most commonly used murine model of
hereditary retinal degeneration28 and the mice are readily
commercially available as pathogen-free animals as required for
housing in a vivarium under immunosuppression. Other
mouse strains with slower retinal degeneration are not readily
available from vendors. However, the retinal degeneration in
rd1 mice is severe and rapidly progressive, potentially making
this model less ideal for detecting a therapeutic effect. A
FIGURE 5. Results of microarray analysis of the RNA from the retina of rd1 mice showing the major gene expressions in the apoptosis pathway that
are altered following intravitreal CD34þ cell injection compared with PBS injection. (A) At 1 week following intravitreal injection. (B) At 4 weeks
following intravitreal injection. Green indicates down-regulation, and red indicates up-regulation.
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previous study exploring intravitreal autologous lineage-nega-
tive BM cell therapy used this rd1 model combined with a
slower model of retinal degeneration (rd10) to show a
therapeutic effect of murine lineage-negative cells in slowing
retinal degeneration.11 The cell therapy was administered
when mice were 2 weeks of age. In our study, the cell therapy
was initiated at a later time point (i.e., 4 weeks of age). This is
because in our study the mice had to be immunosuppressed
for 5 days before initiation of human stem cell therapy and safe
dosing of systemic immunosuppression in younger mice would
be difficult as they experience a rapid growth phase. Because
the rd1 mice typically have a flat ERG signal by 4 weeks of age,
the CD34þ cell therapy was administered at an advanced stage
of retinal degeneration.
Nonetheless, this murine model of rapid retinal degenera-
tion revealed some important information about the behavior
of human CD34þ cells in eyes with retinal degeneration.
Although no functional differences could be detected by ERG
either at 1 or 4 weeks following CD34þ cell therapy, important
molecular changes were detected in the mouse retina on
microarray analysis consistent with a potential trophic
regenerative effect on the degenerating photoreceptors. The
expression of more than 300 different mouse genes in the
retina was altered by human CD34þcell therapy within 1 week
following cell administration. The most prominently affected
genes were those involved in phototransduction, photorecep-
tor development or maintenance, and apoptosis. These
molecular alterations were attenuated at 4 weeks following
cell administration, although the injected cells were still
detected in the eye. The attenuated effect likely reflects the
advanced, perhaps near end-stage nature of the retinal
degeneration at this later study time point. Retinal OCT images
at 4 weeks following cell injection show a complete loss of the
outer retinal layers. This diffuse loss of viable outer retinal
tissue would result in attenuation of any response to cell
therapy. These observations may have implications for
designing an effective clinical trial to study the effects of cell
therapy on progressive degenerative retinal conditions. A
limited time window may be present where therapeutic effect
may be observed as functional improvement.9
The above microarray findings are of note because there are
no prior preclinical studies characterizing the molecular effect
of intravitreal human CD34þ cells on the degenerating retina.
Although human BM CD34þ cells are considered hematopoi-
etic cells, the cell surface markers used to identify these human
hematopoietic cells are different from cell surface markers
used to identify murine hematopoietic cells, and murine
CD34þ cells behave differently from human CD34þ cells.9
Human CD34þ cells have been used successfully for BM
transplantation in patients with hematologic disorders. How-
ever, these CD34þ cells are thought to consist of a
heterogeneous group of cells. Currently, human CD34þ cells
are being explored as a potential regenerative therapy for
ischemic conditions, such as ischemic cardiomyopathy or
peripheral ischemia, because this cell population includes
endothelial progenitor cells.13
There is no published information on the potential neuro-
protective effects of CD34þ cells on the degenerating retina.
However, these cells appear to be recruited from the BM to the
degenerating retina and retinal pigment epithelium. An
elevated level of CD34þ cells in the circulation has been noted
in patients with active exudative AMD.29 In addition, in an
animal model of retinal pigment epithelial degeneration, BM
CD34þ stem cells have been detected to be recruited to the
site of degeneration.30
In this study, CD34þ cells were isolated from the
mononuclear cellular fraction of the BM aspirate using a
magnetic cell sorter, similar to the method used for the
ongoing clinical study.8 The number of CD34þ cells injected
intravitreally in mice is similar to the number of cells that have
been injected in human eyes as part of the clinical trial when
adjusted for differences in vitreous volume between species.
The isolated CD34þ cells were labeled with EGFP prior to
intravitreal injection to follow the migration of these cells
within the eye using in vivo retinal imaging and immunohis-
tochemistry.
The study results show evidence that intravitreally injected
CD34þ cells from human BM can migrate to the retinal surface
and become tightly associated with the retina. Although
transretinal migration of CD34þ cells was not detected in this
study, some intraretinal hyperreflective changes were noted on
OCT, resembling those observed with the in vivo cellular
retinal imaging using adaptive optics OCT (AO-OCT) imaging
of the retina in a patient with hereditary macular degeneration
in the clinical trial.8 These in vivo imaging changes within the
retina are likely related to the presence of the CD34þ cells.
The results of in vivo SLO-OCT retinal imaging conducted in
murine eyes in this study show some important differences
compared with the AO-OCT images on the human subject.
Because of the smaller size of the murine eye and relatively
large pupil compared with the human eye (which result in a
higher numerical aperture), as well as the application of a
contact lens, the combined in vivo SLO and OCT retinal
imaging could be used to achieve near cellular axial and lateral
resolution of the images of the retina without incorporating
AO.31 Perhaps because of these differences in imaging
techniques, the intraretinal reflective changes noted in the
murine retina following CD34þ cell therapy were more subtle
that those noted in the human study. In fact, the majority of the
injected CD34þ cells appear to be attached to the retinal
surface in a diffuse sheet-like manner, creating a dramatic saw-
tooth appearance to the retina surface on OCT B-scan imaging
of the murine retina. No such retinal surface changes were
noted in the human subjects using OCT or AO-OCT imaging.8
There are several possible explanations for this observed
difference. First, it is possible that the vitreo-retinal interface in
these murine eyes with hereditary retinal degeneration might
differ from that in human eyes with hereditary retinal
degeneration, and the difference might affect the chemotactic
signal or migration behavior of these cells. Some species
variation in retinal penetration of intravitreally injected
proteins or drugs have been observed.32,33 Second, the
possible effect of concurrent systemic immunosuppression
on the migration and behavior of the CD34þ cells cannot be
ruled out. Previous cross-species studies using human CD34þ
cells in mice have not used as extensive systemic immunosup-
pression as was used in this study, because these prior studies
were short-term studies.33,34 These earlier studies have shown
retinal vascular incorporation and transretinal migration of
intravitreally injected human CD34þ cells in animal models of
diabetic retinopathy or laser retinal injury. Last, the less
dramatic intraretinal incorporation of the injected cells seen
in this current study could represent some loss of viability of
these cells following isolation and overnight incubation of the
CD34þ cells for EGFP labeling. However, this is unlikely
because long-term intraretinal viability of these cells has been
demonstrated in previous works using NOD-SCID mice,15 and
the extent of detection of EGFP-labeled CD34þ cells in the
retina was unchanged at 1 and 4 weeks after injection in our
current study. In addition, previous studies have shown that
human CD34þ cells can be stably transduced by lentiviral
vectors.18 Nonetheless, the injected CD34þ cells likely secrete
factors such as cytokines and microRNAs that traverse the
retina and induce changes in the retinal cells. This paracrine
effect would explain the molecular changes within the mouse
retina noted in this study following CD34þ cell injection, even
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in the absence of detectable migration of CD34þ cells through
the retina to the degenerating outer retina.
The potential therapeutic effect of the intravitreally injected
CD34þ cells on the degenerating retina is evident based on the
dramatic molecular changes within the mouse retina detected
using microarray analysis despite the relatively advanced stage
of murine retinal degeneration at the time of cell therapy.
Because these molecular changes in the mouse retina were
noted in the absence of any detectable direct incorporation of
the CD34þ cells into the degenerating photoreceptor layer of
the retina, a paracrine trophic effect is implicated. The findings
are analogous to results of a previous study using intravitreal
autologous lineage negative hematopoietic bone marrow cells
in mice. The injected murine cells were localized to the retinal
vasculature, although some preservation of the cones and
down-regulation of apoptotic genes were noted.11
CD34þ cells are an attractive candidate for stem cell therapy,
as they can be obtained relatively easily from patients, require
minimal manipulation prior to administration, and can be used
in an autologous procedure, thus obviating the need for finding
a compatible donor or for immunosuppression. Our previous
work has established that they are capable of integrating into the
retinal vasculature in NOD-SCID mice with acute ischemia-
reperfusion injury following intravitreal injection, and remain
there long term with no ocular and systemic adverse effects.15
In our current study, intravitreal injection of human BM CD34þ
cells was well tolerated in eyes with hereditary retinal
degeneration with no ocular or systemic adverse effects noted
during the course of the study. Results indicate that the cells
were able to survive in murine eyes for at least 4 weeks. Even
though no changes in retinal function could be demonstrated by
ERG in these eyes with advanced retinal degeneration, the gene
expression changes in the degenerating retina were demonstrat-
ed by microarray analysis in eyes treated with CD34þ cells.
Alterations in the expression of genes for proteins regulating
photoreceptor preservation and apoptosis suggest a potential
therapeutic effect on retinal degeneration that warrants further
investigation. In addition, alterations in noncoding RNAs
associated with CD34þ cell injection further support a potential
therapeutic effect of this cell therapy because noncoding RNAs
are known to have key roles in gene expression regulation at the
posttranscriptional level.
Our study had several limitations. First, systemic immuno-
suppression was used to allow human cell engraftment in
transgenic, immune competent mice, which may have
influenced the behavior of the injected CD34þ cells and the
degenerating retina. Second, although EGFP labeled the
majority of the isolated CD34þ cells, the labeling was not
complete and may not have been strong enough to detect all of
the CD34þ cells in the eyes. Because the isolation of CD34þ
cells from BM yields a relatively small amount of these cells,
flow cytometry was not performed on the CD34þ cells
following EGFP labeling to determine the percentage of cells
labeled with EGFP after transduction. Nonetheless, previous
studies have demonstrated that this method of transduction
using a lentiviral vector achieves a relatively high rate of
transduction in CD34þ cells.18 Additional immunohistochem-
ical analysis using anti-human nuclei antibody revealed results
similar to studies using anti-EGFP antibody (i.e., no human cells
were identified beyond the superficial layers of the retina).
Although incorporation of the cells into the outer retina could
not be clearly demonstrated by immunohistochemistry, this
possibility cannot be ruled out. Transretinal migration of
CD34þ cells following intravitreal injection has been demon-
strated previously using a retina laser injury model.34 Third,
treating the mice at almost 4 weeks of age likely attenuated the
potential therapeutic effects of the CD34þ cells on the
degenerating retina. The rd1 retinal degeneration is very rapid
and severe, and it is possible that a more robust therapeutic
effect might be achieved in murine models with slower rate of
retinal degeneration, such as rd10 or rd19. These mice with
slower retinal degeneration were not readily available for the
current study. Despite these limitations, the findings of this
study support further investigation of the therapeutic potential
of CD34þ cells on the degenerating retina.
In conclusion, this study sheds new light on the behavior of
human CD34þ cells following intravitreal injection in murine
eyes with retinal degeneration. The dramatic chemotactic
response of the intravitreally injected CD34þ cells to the
degenerating retina is demonstrated using in vivo retinal
imaging and immunohistochemistry by the diffuse, tight
adherence of the cells to the retinal surface. The dramatic
molecular changes induced within the degenerating retina
following this cell therapy support a potential therapeutic
effect that warrants further investigation of intravitreal CD34þ
cell therapy as a potential treatment for retinal degenerative
conditions.
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